The Spravato Controversy: A Row Over the Drug's Efficacy Compels a Reassessment of its Approval

The UK's drug regulator rejected Janssen's esketamine nasal spray. Why did the US FDA approve it?

Related Keywords

Italy ,United States ,United Kingdom ,France ,London ,City Of ,French ,America ,British ,Florian Naudet ,Chiara Gastaldon ,Joanna Moncrieff ,Ioana Cristea ,Rupert Mcshane ,Peter Simons ,Professor Of Psychiatry At University College London ,Drug Administration ,National Health Service ,Health Products ,University Of Verona ,Kaiser Health News ,Neuroscience At King College London ,Royal College ,Institute Of Psychiatry ,United Kingdom Royal College Of Psychiatrists ,Royal College Of Psychiatrists ,Oxford University ,University College London ,British Medical Journal ,College London ,Briefing Document ,Montgomery Asberg Depression Rating Scale ,Benefits Outweigh ,French National Agency ,Lancet Psychiatry ,Esketamine ,Sketamine For Depression ,Da And Esketamine ,Da And Ketamine ,Janssen ,Ketamine ,Etamine For Depression ,Ice And Esketamine ,Ice And Ketamine ,Spravato ,Treatment Resistant Depression ,